1. Home
  2. JELD vs SGMT Comparison

JELD vs SGMT Comparison

Compare JELD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JELD
  • SGMT
  • Stock Information
  • Founded
  • JELD 1960
  • SGMT 2006
  • Country
  • JELD United States
  • SGMT United States
  • Employees
  • JELD N/A
  • SGMT N/A
  • Industry
  • JELD Forest Products
  • SGMT
  • Sector
  • JELD Basic Materials
  • SGMT
  • Exchange
  • JELD Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • JELD 326.7M
  • SGMT 269.2M
  • IPO Year
  • JELD 2017
  • SGMT 2023
  • Fundamental
  • Price
  • JELD $4.60
  • SGMT $9.64
  • Analyst Decision
  • JELD Hold
  • SGMT Strong Buy
  • Analyst Count
  • JELD 8
  • SGMT 5
  • Target Price
  • JELD $7.34
  • SGMT $26.60
  • AVG Volume (30 Days)
  • JELD 1.5M
  • SGMT 2.0M
  • Earning Date
  • JELD 08-04-2025
  • SGMT 08-13-2025
  • Dividend Yield
  • JELD N/A
  • SGMT N/A
  • EPS Growth
  • JELD N/A
  • SGMT N/A
  • EPS
  • JELD N/A
  • SGMT N/A
  • Revenue
  • JELD $3,592,472,000.00
  • SGMT N/A
  • Revenue This Year
  • JELD N/A
  • SGMT N/A
  • Revenue Next Year
  • JELD $3.40
  • SGMT N/A
  • P/E Ratio
  • JELD N/A
  • SGMT N/A
  • Revenue Growth
  • JELD N/A
  • SGMT N/A
  • 52 Week Low
  • JELD $3.27
  • SGMT $1.73
  • 52 Week High
  • JELD $17.70
  • SGMT $10.43
  • Technical
  • Relative Strength Index (RSI)
  • JELD 62.46
  • SGMT 68.58
  • Support Level
  • JELD $4.18
  • SGMT $7.80
  • Resistance Level
  • JELD $4.56
  • SGMT $9.89
  • Average True Range (ATR)
  • JELD 0.22
  • SGMT 0.95
  • MACD
  • JELD 0.09
  • SGMT -0.01
  • Stochastic Oscillator
  • JELD 97.68
  • SGMT 76.43

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: